罕见泌尿生殖系统肿瘤中的抗体-药物偶联物:综述与展望。

IF 2.8 4区 医学 Q2 ONCOLOGY
Current Opinion in Oncology Pub Date : 2025-05-01 Epub Date: 2025-03-19 DOI:10.1097/CCO.0000000000001141
Andre R Kydd, Md Shahid Sarwar, Saad Atiq, Raju Chelluri, Sandeep Gurram, Elias Chandran, Nicholas Simon, Ian Stukes, Sally Weng, Abbas Yousefi-Rad, A Rouf Banday, Salah Boudjadi, Andrea B Apolo
{"title":"罕见泌尿生殖系统肿瘤中的抗体-药物偶联物:综述与展望。","authors":"Andre R Kydd, Md Shahid Sarwar, Saad Atiq, Raju Chelluri, Sandeep Gurram, Elias Chandran, Nicholas Simon, Ian Stukes, Sally Weng, Abbas Yousefi-Rad, A Rouf Banday, Salah Boudjadi, Andrea B Apolo","doi":"10.1097/CCO.0000000000001141","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>Rare cancers of the genitourinary (GU) tract are often clinically aggressive yet have few or no standard-of-care treatments. Multiple antibody-drug conjugates (ADCs) have been approved in solid malignancies. This review explores the use of ADCs in rare GU tumors in the context of biological pathways and ongoing research in solid tumors.</p><p><strong>Recent findings: </strong>Few clinical trials of ADCs focus on recruiting participants with rare tumors of the GU tract, including trials testing enfortumab vedotin as monotherapy or combined with pembrolizumab, and sacituzumab govitecan as monotherapy or combined with atezolizumab. We highlight many ongoing trials of novel ADCs for advanced/metastatic solid tumors and emphasize the potential eligibility of patients with rare GU tumors for tumor-agnostic trials.</p><p><strong>Summary: </strong>ADCs are being tested in multiple solid tumors, including rare GU tumors. Ongoing preclinical research supports the use of some ADCs in several rare GU tumors and improves our understanding of their pathophysiology.</p>","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"250-258"},"PeriodicalIF":2.8000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970986/pdf/","citationCount":"0","resultStr":"{\"title\":\"Antibody-drug conjugates in rare genitourinary tumors: review and perspectives.\",\"authors\":\"Andre R Kydd, Md Shahid Sarwar, Saad Atiq, Raju Chelluri, Sandeep Gurram, Elias Chandran, Nicholas Simon, Ian Stukes, Sally Weng, Abbas Yousefi-Rad, A Rouf Banday, Salah Boudjadi, Andrea B Apolo\",\"doi\":\"10.1097/CCO.0000000000001141\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose of review: </strong>Rare cancers of the genitourinary (GU) tract are often clinically aggressive yet have few or no standard-of-care treatments. Multiple antibody-drug conjugates (ADCs) have been approved in solid malignancies. This review explores the use of ADCs in rare GU tumors in the context of biological pathways and ongoing research in solid tumors.</p><p><strong>Recent findings: </strong>Few clinical trials of ADCs focus on recruiting participants with rare tumors of the GU tract, including trials testing enfortumab vedotin as monotherapy or combined with pembrolizumab, and sacituzumab govitecan as monotherapy or combined with atezolizumab. We highlight many ongoing trials of novel ADCs for advanced/metastatic solid tumors and emphasize the potential eligibility of patients with rare GU tumors for tumor-agnostic trials.</p><p><strong>Summary: </strong>ADCs are being tested in multiple solid tumors, including rare GU tumors. Ongoing preclinical research supports the use of some ADCs in several rare GU tumors and improves our understanding of their pathophysiology.</p>\",\"PeriodicalId\":10893,\"journal\":{\"name\":\"Current Opinion in Oncology\",\"volume\":\" \",\"pages\":\"250-258\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970986/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Opinion in Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/CCO.0000000000001141\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/19 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CCO.0000000000001141","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

综述目的:泌尿生殖系统(GU)道的罕见癌症通常具有临床侵袭性,但很少或没有标准的治疗方法。多种抗体-药物偶联物(adc)已被批准用于实体恶性肿瘤。本文综述了adc在罕见GU肿瘤中的生物学途径和正在进行的实体肿瘤研究中的应用。最近的发现:很少有adc的临床试验关注于招募患有罕见的GU道肿瘤的参与者,包括测试enfortumab vedotin作为单一疗法或与pembrolizumab联合的试验,以及sacituzumab govitecan作为单一疗法或与atezolizumab联合的试验。我们强调了许多正在进行的用于晚期/转移性实体瘤的新型adc的试验,并强调了罕见GU肿瘤患者进行肿瘤不确定试验的潜在资格。adc正在多种实体肿瘤中进行测试,包括罕见的GU肿瘤。正在进行的临床前研究支持在几种罕见的GU肿瘤中使用一些adc,并提高了我们对其病理生理的理解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Antibody-drug conjugates in rare genitourinary tumors: review and perspectives.

Purpose of review: Rare cancers of the genitourinary (GU) tract are often clinically aggressive yet have few or no standard-of-care treatments. Multiple antibody-drug conjugates (ADCs) have been approved in solid malignancies. This review explores the use of ADCs in rare GU tumors in the context of biological pathways and ongoing research in solid tumors.

Recent findings: Few clinical trials of ADCs focus on recruiting participants with rare tumors of the GU tract, including trials testing enfortumab vedotin as monotherapy or combined with pembrolizumab, and sacituzumab govitecan as monotherapy or combined with atezolizumab. We highlight many ongoing trials of novel ADCs for advanced/metastatic solid tumors and emphasize the potential eligibility of patients with rare GU tumors for tumor-agnostic trials.

Summary: ADCs are being tested in multiple solid tumors, including rare GU tumors. Ongoing preclinical research supports the use of some ADCs in several rare GU tumors and improves our understanding of their pathophysiology.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Opinion in Oncology
Current Opinion in Oncology 医学-肿瘤学
CiteScore
6.10
自引率
2.90%
发文量
130
审稿时长
4-8 weeks
期刊介绍: With its easy-to-digest reviews on important advances in world literature, Current Opinion in Oncology offers expert evaluation on a wide range of topics from sixteen key disciplines including sarcomas, cancer biology, melanoma and endocrine tumors. Published bimonthly, each issue covers in detail the most pertinent advances in these fields from the previous year. This is supplemented by annotated references detailing the merits of the most important papers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信